藥物成份

共有 21645 個藥物成份

PROTEOLYSIS L.M. FROM GELATIN BY ENZYMATIC HYDROLY

• 關聯藥證數量: 1

PROTEUS VULGARIS

• 關聯藥證數量: 1

PROTOKYLOL

• 關聯藥證數量: 1

PROTOPORPHYRIN SODIUM

• 關聯藥證數量: 1

PROTOVERATRINE A

• 關聯藥證數量: 1

PRUNI CER. FLD EXTRACT

• 關聯藥證數量: 1

PRUNUS MUME EXTRACT

• 關聯藥證數量: 1

PSA Bead Pack:\ncoated with polyclonal goat anti-PSA antibody.\nPSA Reagent Wedge:\nalkaline phosphatase (bovine calf intestine) conjugated to monoclonal murine anti-PSA antibody in buffer.\nPSA Adjustors:\nTwo vials (Low and High) 1.5 mL each of PSA in a chicken serum/buffer matrix.

• 關聯藥證數量: 1

PSA Bead Pack：\nCoated with polyclonal goat anti-PSA antibody.\nPSA Reagent Wedge：\nAlkaline phosphatase(bovine calf intestine) conjugated to monoclonal murine anti-PSA antibody in buffer.\nPSA Adjustors：\nTwo vials(Low and High)1.5 mL each of PSA in a chicken serum/buffer matrix.\n

• 關聯藥證數量: 1

PSA Reagent: Polyclonal goat anti-PSA antibody.\nPSA Sample Diluent: PSA-free chicken serum/buffer matrix.

• 關聯藥證數量: 1

PSA antibodies particles and PSA antibodies coated on the membrane.

• 關聯藥證數量: 1

PSEUDOEPHEDRINE BASE

• 關聯藥證數量: 1

PT2 Pretreatment reagent 2 (gray cap), 1 bottle, 4 mL:\nSodium hydroxide 40 g/L; sodium cyanide 2.205 g/L.

• 關聯藥證數量: 1

PTH Ab-Coated Tubes (IPH1): coated with affinity-purified polyclonal goat antibodies to PTH (44-84)\n125I PTH Ab (IPH2): Lyophilized reagent, consisting of iodinated anti-PTH (1-34) affinity-purified polyclonal goat antibody\nIntact PTH Calibrators (PH13-9): lyophilized intact PTH calibrators in a human serum matrix\nIntact PTH Controls (PHCO1-2): Synthetic human intact PTH in a human protein-based matrix.

• 關聯藥證數量: 1

PTH Zero Standard: Reagent C One vial containing 4.0 mL of PTH-free human serum.\nPTH Standards: Reagent D2-H One vial each containing 2.0 mL of synthetic intact PTH in buffered protein solution containing human serum.\nWash Solution Concentrate: Reagent I One vial containing 50 mL of a surfactant in phosphate buffered saline.\nPTH Controls: Reagent J & K One vial containing 2.0 mL of synthetic intact PTH in buffered protein solution containing human serum.\nPTH Standard: Reagent D1 One vial containing 2.0 mL of synthetic intact PTH in buffered protein solution containing human serum

• 關聯藥證數量: 1

PU film聚氨酯膜100%;\nSilicate silver 矽片銀1.5%;\nPressure Sensitive Adhesive 感壓膠68.5%;\nSodium Carboxymethyl Cellulose, 羧甲基纖維素鈉30%;\nLiner 離型紙100%\n以下空白\n

• 關聯藥證數量: 1

PUERARIAE RADIX

• 關聯藥證數量: 1

PULSATILLE

• 關聯藥證數量: 1

PULVERIZED SCOPOLIA EXTRACT

• 關聯藥證數量: 1

PULVIS RADIX LIQUIRITIAE

• 關聯藥證數量: 1

PULVIS RADIX PLATICODI

• 關聯藥證數量: 1

PULVIS RADIX POYGALAE

• 關聯藥證數量: 1

PULVIS SEMEN ARMENIACAE

• 關聯藥證數量: 1

PUMILIO PINE OIL (DWARF PINE NEEDLE OIL)

• 關聯藥證數量: 1

PURE FOOD GLAZE

• 關聯藥證數量: 1

PURIFIED

• 關聯藥證數量: 1

PURIFIED EGG PHOSPHOLIPIDS

• 關聯藥證數量: 1

PURIFIED PERFLUORO-N-OCTANE

• 關聯藥證數量: 1

PURIFIED STRUCTURED TRIGLYCERIDE

• 關聯藥證數量: 1

PURIFIED TALC SPECIAL

• 關聯藥證數量: 1

PWBG432-Glucose/Hemoglobin poc 3郵件x2標本x2ml 液體，全血\nPBGA432-Blood Gas/Electrolytes poc 3郵件x2標本x2.5ml 體液\nPUCR432-Urea/Creatinine poc 3郵件x2標本x1ml 液體，新鮮人體血清\nPHCR432-Hematocrit poc 3郵件x2標本x1ml 體液PCAM432-Cardiac Markers-plasma poc 3郵件x2標本x1ml 液體，新鮮人體血漿\nPBLP432-Basic Lipids poc 3郵件x2標本x5ml 液體，血清\nPURD432-Urine Drug Screen poc 3郵件x2標本x10ml 液體，新鮮人體尿液\nNITZ431-Nitrazine Testing 3郵件x1標本x2ml 液體PWBP432-Whole Blood Prothrombin time poc 3郵件x2標本x1ml 凍乾全血\nPPLP432-Plasma Prothrombin Time poc 3郵件x2標本x1ml 凍乾血漿

• 關聯藥證數量: 1

PYLORIC EXTRACT WITH INTRINSIC FACTOR ACTIVITY (EQ TO PYLORIC EXTRACT WITH INTRINSIC FACTOR CONCENTRATE 3.75mg)

• 關聯藥證數量: 1

PYR Disks: L-pyrrolidonyl-β-naphthylamide\nColor Developer: 0.01% p-dimethylaminocinnamalldehyde

• 關聯藥證數量: 1

PYRANTEL EMBONATE

• 關聯藥證數量: 1

PYRIDOFYLLINE

• 關聯藥證數量: 1

PYRIDOXAL PHOSPHATE SODIUM

• 關聯藥證數量: 1

PYRIDOXAL TRISPALMITATE

• 關聯藥證數量: 1

PYRIDOXINE DIOCTANOATE

• 關聯藥證數量: 1

PYRIDOXINE HYDROGEN PHOSPHATE H2O

• 關聯藥證數量: 1

PYRILAMINE TANNATE

• 關聯藥證數量: 1

PYRISUCCIDEANOL DIMALEATE

• 關聯藥證數量: 1

PYROGLUTAMATE DL- SODIUM

• 關聯藥證數量: 1

PYROVALERONE

• 關聯藥證數量: 1

PYROZYME

• 關聯藥證數量: 1

PYRROLIDINONE POLYMER

• 關聯藥證數量: 1

PYRROLNITRIN

• 關聯藥證數量: 1

PYRUVIC ACID

• 關聯藥證數量: 1

PYRVINIUM

• 關聯藥證數量: 1

Package Insert (1).

• 關聯藥證數量: 1

Paclitaxel (2nd) contains not less than 97.0 percent and not more than 102.0 percent of C47H51NO14 calculated on the anhydrous basis.

• 關聯藥證數量: 1

Paclitaxel contains not less than 97.0 percent and not more than 102.0 percent of C47H51NO14.

• 關聯藥證數量: 1

Paclitaxel contains not less than 97.0% and not more than 102.0% of C47H51NO14, calculated on the anhydrous, solvent-free basis.

• 關聯藥證數量: 1

Paclitaxel contains not less than 99.0% and not more than 101.0% of C47H51NO14, calculated on the anhydrous, solvent-free basis.

• 關聯藥證數量: 1

Paliperidone contains NLT 98.0% and NMT 102.0% of Paliperidone (C23H27FN4O3).

• 關聯藥證數量: 1

Paliperidone contains not less than 98.0% and not more than 102.0% of C23H27FN4O3, calculated on dried basis.

• 關聯藥證數量: 1

Paliperidone contains not less than 98.0% and not more than 102.0% of C23H27FN4O3, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Palonosetron Hydrochloride contains 98.0% ~ 102.0% of C19H24N2O‧HCl, calculated on the dried basis

• 關聯藥證數量: 1

Panitumumab

• 關聯藥證數量: 1

Panoscreen I & II : a two-vial set. Each vial contain a 2-4% suspension of single donor, group O red cells prepared in a buffered preservative solution containing adenosine and adenine to retard hemolysis and/or loss of antigenicity during the dating period. Chloramphenicol(0.25 mg/mL), neomycin sulfate(0.1mg/mL) and gentamycin sulfate(0.05mg/mL) have been added as preservatives.

• 關聯藥證數量: 1

Pantoprazole Sodium Contains not less than 99 percent and not more than 101 percent of C16H14F2N3NaO4S, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Pantoprazole Sodium Sesquihydrate contains not less than 99.0% and not more than 101.0% of C16H14F2N3NaO4S‧1 1/2H2O, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Pantoprazole Sodium Sesquihydrate contains not less than 99.0% and not more than 101.0%.

• 關聯藥證數量: 1

Pantoprazole Sodium Sesquihydrate, Content: 99.0 per cent to 101.0 per cent (anhydrous substance).

• 關聯藥證數量: 1

Pantoprazole Sodium contains NLT 98.0% and NMT 102.0% of C16H14F2N3NaO4S．3/2 H2O, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Pantoprazole Sodium contains not less than 98.0% and not more than 102% of C16H14F2N3NaO4S, calculated on anhydrous basis.

• 關聯藥證數量: 1

Pantoprazole Sodium contains not less than 98.0% and not more than 102.0% of C16H14F2N3NaO4S, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Pantoprazole Sodium contains not less than 99% and not more than 101% of C16H14F2N3NaO4S, calculated on the dried basis.

• 關聯藥證數量: 1

Pantoprazole hemimagnesium monohydrate

• 關聯藥證數量: 1

Pantothenol (Dexpanthenol) contains not less than 98.0% and not more than 102% of dexpantothenol(C9H19NO4), calculated on the anhydrous basis.

• 關聯藥證數量: 1

Paracetamol N-(4-Hydroxyphenyl)acetamide. Content:99.0 per cent to 101.0 per cent (dried substance).

• 關聯藥證數量: 1

Paracetamol (Acetaminophen) contains not less than 99.0% and not more than 101.0% of C8H9NO2, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Paracetamol (Acetaminophen) contains not less than 99.0% and not more than 101.0% of C8H9NO2, calculated on the dried substance.

• 關聯藥證數量: 1

Paracetamol contains 99.0%~101% of C8H9NO2, calculated on dried basis.

• 關聯藥證數量: 1

Paracetamol contains not less than 99% and not more than 101% of C8H9NO2, calcuclated on the anhydrous basis.

• 關聯藥證數量: 1

Paracetamol contains not less than 99.0 per cent and not more than the equivalent of 101.0 per cent of C8H9NO2 calculated with reference to the dried substance.

• 關聯藥證數量: 1

Paracetamol contains not less than 99.0% and not more than 101.0% of C8H9NO2, calculated on the dried substance.

• 關聯藥證數量: 1

Paracetamol contains not less than 99.0% and not more than the equivalent of 101.0% of C20H21NO4,HCl, calculated with reference to the dried substance.

• 關聯藥證數量: 1

Paracetamol contaions not less than 99.0% and not more than 101.0% of C8H9NO2,calculated on the dried substance.

• 關聯藥證數量: 1

Parainfluenza 1 monoclone antibidy conjugated FITC,\nParainfluenza 2 monoclone antibidy conjugated FITC,\nParainfluenza 3 monoclone antibidy conjugated FITC,\nPositive Control Slide,\nMounting medium.

• 關聯藥證數量: 1

Parecoxib Sodium contains not less than 98.0% w/w and not more than 102.0% w/w of C19H17N2O4SNa (on anhydrous and solvent free basis)

• 關聯藥證數量: 1

Parecoxib Sodium contains NLT 98.0% and NMT 102.0% of C19H17N2NaO4S, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Parecoxib Sodium contains not less than 98.0% and not more than 102.0% of C19H17N2O4SNa, calculated on the dried basis.

• 關聯藥證數量: 1

Parecoxib Sodium contains not less than 98.5% and not more than 101.5% of C19H17N2O4SNa, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Parecoxib Sodium contains not less than 98.5% and not more than 102.0% of C19H17N2O4SNa, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Parecoxib sodium contains not less than 98.0% and not more than 102.0% of C19H17N2O4SNa, calculated on the anhydrous basis.

• 關聯藥證數量: 1

Paricalcitol contains 97.0%~103.0% (dried basis)

• 關聯藥證數量: 1

Paritaprevir

• 關聯藥證數量: 1

Parotitis Virus: 1. Antigen 2. Control Antigen 3. Postive Control 4. Negative Control.

• 關聯藥證數量: 1

Paroxetine Hydrochloride Hemihydrate contains not less than 97.5% and not more than 102.0% of C19H21ClFNO3‧1/2H2O, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Paroxetine Hydrochloride Hemihydrate contains not less than 98.5% and not more than 102.0% of C19H20FNO3 · HCl · ½H2O, calculated on the anhydrous and solvent-free basis.

• 關聯藥證數量: 1

Paroxetine Hydrochloride Hemihydrate contains not less than 98.5% and not more than 102.0% of C19H21ClFNO3‧1/2H2O, calculated on the anhydrous substance.

• 關聯藥證數量: 1

Paroxetine Hydrochloride contains not less than 98.5 percent and not more than 102.0 percent of C19H20FNO3‧HCl, calculated on the anhydrous and solvent-free basis.

• 關聯藥證數量: 1

Paroxetine Hydrochloride hemihydrate Content: 98.5% to 101.5% (Anhydrous substance)

• 關聯藥證數量: 1

Part A Substrate ─urea peroxide.

• 關聯藥證數量: 1

Part A: DNA Pol. (red cap) 1 x 55 μL, TSM (orange cap) 2 x 1.1 mL\nPart B: E1 1 x 20 mL, E2 8 x 1.3 mL, DR. Hyb Buffer 1 x 15 mL, Blocking Reagent 1 x 80 mL, Strep-AP (colorless cap) 2 x 30 μL, NBT/BCIP (brown cap) 2 x 0.6 mL, Detection Buffer 1 x 120 mL, Wash Buffer 2 x 200 mL, DR. TB-SC Chip 12 x 8 Rx, 96 Well Plate Cage 1 case, Plastic Membrane 1 Piece, User’s Guide 1 set\n

• 關聯藥證數量: 1

Part B Substrate─tetramethylbenzidine.

• 關聯藥證數量: 1

Particle Bound Anti-Streptolysin O (Recombinant) 691ug/mL

• 關聯藥證數量: 1

Particle Bound Human Gamma Globulin 6591 ug/mL

• 關聯藥證數量: 1

Particle Bound Theophylline:4.7 mL;Mouse Monoclonal Anti-Theophylline: 5.2mL

• 關聯藥證數量: 1

Particle Reagent, Buffer, and Antibody.

• 關聯藥證數量: 1